Schizophrenia treatment is complicated by a constellation of persistent barriers that Michael McGuire, PharmD, BCPP, professor of pharmacy practice at Belmont University College of Pharmacy and Health Sciences, encounters routinely in his inpatient behavioral health practice. Chief among them are prior authorizations, which pose a particular challenge given schizophrenia's heterogeneous nature; what works for one patient rarely works for all, and treatment frequently requires trial and error. Newer agents and long-acting injectable (LAI) antipsychotics are especially vulnerable to coverage delays, compounded by a growing shift of LAIs from pharmacy benefits to medical benefits, a distinction many pharmacies are ill-equipped to navigate.
Key Takeaways
- Prior authorizations and the shift of LAIs from pharmacy to medical benefits create compounding access barriers that can prevent patients with schizophrenia from receiving guideline-recommended treatments.
- Only about one-third of patients initiated on monthly LAI antipsychotics during a hospitalization follow through with their next injection.
- Expanding pharmacist administration of LAIs could eliminate at least one logistical stop for patients who currently must travel to separate locations to pick up, administer, and manage their mental health medications.
Transitions of care represent another critical failure point. Patients with schizophrenia often struggle with cognitive impairment and health system navigation, making the handoff between inpatient and outpatient settings especially fraught. Medications are missed, discharge instructions go unread, and errors accumulate in a system that McGuire describes as fractured even for providers.
LAIs offer a meaningful opportunity to improve outcomes—they have demonstrated reductions in rehospitalization and support long-term stability—but only if patients actually receive them consistently. McGuire notes that only about one-third of patients initiated on monthly LAIs during a hospitalization show up for their next injection. A primary driver is the shortage of outpatient injection sites, particularly in rural areas where small private practices and community mental health clinics frequently do not administer these medications.
Broader adoption is also hampered by stigma, misconceptions about coercion, cost pressures on hospital pharmacy budgets, and inconsistent policies around manufacturer-supplied product. Expanding pharmacist administration of LAIs could meaningfully reduce the logistical burden patients face in accessing these treatments.
